Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
6.92
+6.73 (3,571.09%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Scilex Holding Company Revenue
In the year 2024, Scilex Holding Company had annual revenue of $56.59M with 21.07% growth. Scilex Holding Company had revenue of $14.90M in the quarter ending December 31, 2024, with 10.68% growth.
Revenue (ttm)
$56.59M
Revenue Growth
+21.07%
P/S Ratio
0.46
Revenue / Employee
$492,087
Employees
115
Market Cap
36.23M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SCLX News
- 15 hours ago - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada - GlobeNewsWire
- 4 days ago - Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewsWire
- 20 days ago - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 - GlobeNewsWire
- 2 months ago - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - GlobeNewsWire
- 3 months ago - Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - GlobeNewsWire